Filter
17
Featured
Language
Document type
Studies & Reports
16
Guidelines
1
Authors & Publishers
The Lancet Journal
3
World Health Organization WHO
3
Organisation Mondiale de la Santé OMS
2
A. Erbowor-Becksen, R. Yotsu, et al.
1
Aboagye, S. Y.
1
Current Tropical Medicines Report
1
Dove Medical Press Limited
1
Emerging Infectious Diseases (EID) Journal
1
et al
1
F. S.Sarfo, M. Sarpong Duah, et al.
1
Frimpong, M.
1
Hope Simpson, Kebede Deribe, Earnest Njih Tabah, Adebayo Peters et al.
1
J. Robert, K. Mohamed Abass et al.
1
Johnson, P.D.R.
1
K. Suzuki, R. E. Simmonds et al.
1
Muleta, A.J., R. Lappan, T. P. Stinear, et al.
1
Muntean Al., Popa M.
1
Omansen, T.F.
1
Otchere, I. D.
1
Phillips, O.
1
PLoS Neglected Tropical Diseases
1
Pluschke, G., and K. Röltgen
1
Popa G.
1
R. Bieri, S.S. Thomas, et al.
1
S.A.
1
Sakyi
1
Scherr, N.
1
Springer Nature
1
The Canadian Journal of Infectious Diseases & Medical Microbiology
1
WHO Tecnical Advisory Group and FIND
1
Yotsu,R.R.
1
Publication Years
Category
Buruli Ulcer
1
Laboratory Technologies
1
Toolboxes
The development of this target product profile (TPP) was led by the WHO Department of Control of Neglected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG) was form... more
The Lancet Global Health Volume 7, ISSUE 7, e912-e922, July 01, 2019
Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now be the cornerstone of the treatment of... more
The Lancet olume 395, ISSUE 10232, P1259-1267, April 18, 2020. Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifa... more
August 26, 2021 https://doi.org/10.1371/journal.pntd.0009678
The meeting was held from 26 to 27 March 2018 to review and discuss the following topics: Advances and challenges in the use of fTLC, and new approaches to detecting mycolactone using monoclonal antibodies (mAbs). The status of development of rapid diagnostic tests (RDTs) targeting the MUL... more
Volume 2016 | Article ID 5310718 | https://doi.org/10.1155/2016/5310718. Buruli ulcer (BU) is a necrotizing cutaneous infection caused by Mycobacterium ulcerans. Early diagnosis is crucial to prevent morbid effects and misuse of drugs. We review developments in laboratory diagnosis of BU, discuss li... more
Au total, 18 laboratoires de 13 pays ont participé aux quatre cycles d'AQE : 10 laboratoires de huit pays africains endémiques, dont quatre ont participé aux quatre cycles et trois à trois cycles. Les résultats globaux ont montré que la performance médiane de ces laboratoires s'est amélioré... more
The World Health Organization (WHO) convened a meeting of the Technical Advisory Group on Buruli ulcer at its headquarters in Geneva, Switzerland on 25 to 27 March 2019
Current Tropical Medicine Reports (2018) 5:247–256 https://doi.org/10.1007/s40475-018-0166-2 .Purpose of the Review Buruli ulcer (BU) is a necrotizing and disabling cutaneous disease caused by Mycobacterium ulcerans, one of the skin-related neglected tropical diseases (skin NTDs). This article aim... more
A major objective of this open access book is to summarize the current status of Buruli Ulcer (BU) research for the first time. It will identify gaps in our knowledge, stimulate research and support control of the disease by providing insight into approaches for surveillance, diagnosis, and treatmen... more
Buruli ulcer caused by Mycobacterium ulcerans is a neglected tropical disease characterized by extensive ulceration involving predominantly the upper and lower limbs of patients. The disease is common in rural tropical communities in West and Central Africa, where access to proper health care is lim... more
Nat Commun 9, 5370 (2018). https://doi.org/10.1038/s41467-018-07804-8. Mycobacterium ulcerans is the causative agent of Buruli ulcer, a neglected tropical skin disease that is most commonly found in children from West and Central Africa. Despite the severity of the infection, therapeutic options are... more
Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are needed in some cases to ensure full recovery. The targ... more
L’ulcère de Buruli, une infection causée par Mycobacterium ulcerans, touche plus de 33 pays dans le monde, mais un peu moins de la moitié seulement de ces pays communiquent régulièrement des données sur la maladie à l’OMS.
Buruli ulcer (BU) is a bacterial skin infection that is caused by Mycobacterium ulcerans and mainly affects people who reside in the rural areas of Africa and in suburban and beach resort communities in Australia.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 12, December 2019 2183 Buruli ulcer is a neglected tropical disease caused by Myocobacterium ulcerans; it manifests as a skin lesion, nodule, or ulcer that can be extensive and disabling. To assess the global burden and the progress ... more